TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00868413

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-263
Description: ABT-263 is taken orally once daily for 3 days out of each 28 day cycle. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-263
Description: ABT-263 is taken orally once daily for 3 days out of each 28 day cycle. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FCR
Description: Rituximab will be given by intravenous infusion for 1 day out of each 28 day cycle; Fludarabine will be given by intravenous infusion for 3 days out of each 28 day cycle; and Cyclophosphamide will be given by intravenous infusion for 3 days out of each 28 day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BR
Description: Rituximab will be given by intravenous infusion for 2 days out of each 28 day cycle and Bendamustine will be given by intravenous infusion for 2 days out of each 28 day cycle
Study: NCT00275366

Intervention type: DEVICE
Group type: OTHER
Intervention: Robotic Therapy
Study: NCT00925860

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non positive pressure mechanical ventilatory support
Study: NCT01903044

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BM-MNC injection
Description: BM-MNC cells will be injected in aliquots of 1 ml at multiple regions of the leg muscles
Study: NCT01222351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 94-9172 (Florbetaben)
Description: Measure of brain amyloid load using BAY 94-9172 PET/CT
Study: NCT03510702

Intervention type: DIAGNOSTIC_TEST
Intervention: Levels of epigenetic biomarkers present in the gingival fluid and its possible relationship with bone metabolism.
Description: Once the anamnesis has been done, all the records corresponding to the Gingival Index and Plaque Index, in both groups are taken.~Subsequently, samples of gingival crevicular fluid are taken for the screening of epigenetic biomarkers.
Study: NCT01663233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: LCZ696 will use tablets available at a strength of 200mg. Patients will be instructed to take the prescribed medication once a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Amlodipine will use tablets available at a strength of 5 mg. Patients will be instructed to take the prescribed medication once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Amlodipine will use tablets available at a strength of 5 mg. Patients will be instructed to take the prescribed medication once a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo to LCZ696
Study: NCT02697747

Intervention type: OTHER
Intervention: Education
Description: Educational intervention in the use of ultrasound to identify landmarks
Study: NCT03794063

Intervention type: OTHER
Intervention: Robson 10 group classification system
Description: WHO proposed the Robson classification system as a global standard for assessing, monitoring and comparing caesarean section rates within healthcare facilities over time, and between facilities. It classifies women in 10 groups based on their obstetric characteristics (parity, previous CS, gestational age, onset of labour, fetal presentation and number of fetuses) without needing the indication for CS.

Intervention type: OTHER
Intervention: Robson 10 group classification system
Description: WHO proposed the Robson classification system as a global standard for assessing, monitoring and comparing caesarean section rates within healthcare facilities over time, and between facilities. It classifies women in 10 groups based on their obstetric characteristics (parity, previous CS, gestational age, onset of labour, fetal presentation and number of fetuses) without needing the indication for CS.

Intervention type: OTHER
Intervention: Robson 10 group classification system
Description: WHO proposed the Robson classification system as a global standard for assessing, monitoring and comparing caesarean section rates within healthcare facilities over time, and between facilities. It classifies women in 10 groups based on their obstetric characteristics (parity, previous CS, gestational age, onset of labour, fetal presentation and number of fetuses) without needing the indication for CS.
Study: NCT04278560

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Description: tDCS will be delivered via six gel electrodes with placement and current parameters optimized based on a standard brain to maximize the average normal component of the generated electric field over the left dlPFC. Current delivered by anyone electrode will never exceed 2.0 mA; the total amount of current from all electrodes will not exceed 4 mA. Each 20-minute session will begin and end with a 60-second ramp up/down of current amplitude to maximize comfort.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham stimulation
Description: An 'active' sham will be used in which very low-level currents are transferred between the same electrodes used in the active condition throughout the 20-minute session. However, currents will be designed to mimic the cutaneous sensations induced by tDCS yet not significantly influence cortical tissue.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral intervention to increase physical activity
Description: Study staff will complete face-to-face and telephone counseling sessions with each participant, tailored to their state of readiness to increase physical activity levels. The participant will be provided with a goal to increase their average daily step count by 20% from baseline. The staff member will review the participant's stated barriers to exercise and provide them with a list of strategies they may use to augment their step counts throughout each day. Bi-weekly face-to-face counseling sessions will then be completed to review and discuss activity performance and answer any questions the participant may have regarding their efforts to increase physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral intervention to increase physical activity
Description: Study staff will complete face-to-face and telephone counseling sessions with each participant, tailored to their state of readiness to increase physical activity levels. The participant will be provided with a goal to increase their average daily step count by 20% from baseline. The staff member will review the participant's stated barriers to exercise and provide them with a list of strategies they may use to augment their step counts throughout each day. Bi-weekly face-to-face counseling sessions will then be completed to review and discuss activity performance and answer any questions the participant may have regarding their efforts to increase physical activity.
Study: NCT05517681

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: non-ICG
Description: Laparoscopic radical resection of rectal cancer was performed routinely without ICG injection. The separation should extend from the center to the left, reaching the left paracolic sulcus lateral to the genital vessels. The Superior hypogastric nerve is protected by freeing it at the angle of the common iliac artery on both sides, afterwards, the vessel is free along the surface of the plexus from caudal to cephalic side to reach the root of the IMA. Switching lymph node visualization patterns. Based on the operator's experience and the extent of lymph node visualization, the lymph nodes at the root of the IMA were removed with an ultrasonic knife . The dissection continues caudally along the IMA, preserving the arterial sheath. Expose the left colonic artery, superior rectal artery, and sigmoid artery, maximum preservation of the IMA peripheral plexus while clearing their surrounding lymph nodes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICG
Description: Dilute ICG to 2.5 mg/ml with its accompanying sterilized water for injection. Slow injection with a 1ml syringe in 4 parts of the tumor，Inject 0.25ml per site . Procedure started after lymph node visualization.The operation was consistent with the control group.
Study: NCT04574102

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Omega Refractive Capsule with FDA approved Intraocular Lens
Description: Omega Refractive Capsule with FDA approved Intraocular Lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FDA approved Intraocular lens
Description: FDA approved Intraocular lens
Study: NCT03794063

Intervention type: OTHER
Intervention: Robson 10 group classification system
Description: WHO proposed the Robson classification system as a global standard for assessing, monitoring and comparing caesarean section rates within healthcare facilities over time, and between facilities. It classifies women in 10 groups based on their obstetric characteristics (parity, previous CS, gestational age, onset of labour, fetal presentation and number of fetuses) without needing the indication for CS.

Intervention type: OTHER
Intervention: Robson 10 group classification system
Description: WHO proposed the Robson classification system as a global standard for assessing, monitoring and comparing caesarean section rates within healthcare facilities over time, and between facilities. It classifies women in 10 groups based on their obstetric characteristics (parity, previous CS, gestational age, onset of labour, fetal presentation and number of fetuses) without needing the indication for CS.

Intervention type: OTHER
Intervention: Robson 10 group classification system
Description: WHO proposed the Robson classification system as a global standard for assessing, monitoring and comparing caesarean section rates within healthcare facilities over time, and between facilities. It classifies women in 10 groups based on their obstetric characteristics (parity, previous CS, gestational age, onset of labour, fetal presentation and number of fetuses) without needing the indication for CS.

Intervention type: OTHER
Intervention: Robson 10 group classification system
Description: WHO proposed the Robson classification system as a global standard for assessing, monitoring and comparing caesarean section rates within healthcare facilities over time, and between facilities. It classifies women in 10 groups based on their obstetric characteristics (parity, previous CS, gestational age, onset of labour, fetal presentation and number of fetuses) without needing the indication for CS.

Intervention type: OTHER
Intervention: Robson 10 group classification system
Description: WHO proposed the Robson classification system as a global standard for assessing, monitoring and comparing caesarean section rates within healthcare facilities over time, and between facilities. It classifies women in 10 groups based on their obstetric characteristics (parity, previous CS, gestational age, onset of labour, fetal presentation and number of fetuses) without needing the indication for CS.

Intervention type: OTHER
Intervention: Robson 10 group classification system
Description: WHO proposed the Robson classification system as a global standard for assessing, monitoring and comparing caesarean section rates within healthcare facilities over time, and between facilities. It classifies women in 10 groups based on their obstetric characteristics (parity, previous CS, gestational age, onset of labour, fetal presentation and number of fetuses) without needing the indication for CS.
Study: NCT00834249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine 25 mg Tablets
Description: 1 x 25 mg, single-dose fasting
Study: NCT04046302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinoprostone
Description: 1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) self-inserted by participants 3 hours before scheduled IUD insertion appointment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one tablet of placebo self-inserted by participants 3 hours before scheduled IUD insertion appointment.
Study: NCT05220150

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FFC-MRI scan
Description: Undergo one FFC-MRI scan.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FFC-MRI scan
Description: Undergo one FFC-MRI scan.
Study: NCT01870635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Eligible children will receive one weight based (0.13 - 0.26 mg/kg) dose of an oral ondansetron disintegrating tablet. Subsequent therapy will be in accordance with World Health Organization guidelines as dictated by the child's hydration status.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eligible children will receive one dose of an oral disintegrating Placebo (sugar pill) tablet. Subsequent therapy will be in accordance with World Health Organization guidelines as dictated by the child's hydration status.
Study: NCT03102684

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Secondhand exposure to e-cigarette aerosols (low)
Description: Participants will be exposed to secondhand aerosols produced by e-cigarette use. E-cigarette with low resistance will be used by an experienced smoker (tobacco flavor liquid, 12 mg nicotine, 4 sec puffs, 20-30 seconds inter-puff interval). Duration of exposure: 30 minutes.~All study subjects will participate in this arm as the study has a cross-over design.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Secondhand exposure to e-cigarette aerosols (high)
Description: Participants will be exposed to secondhand aerosols produced by e-cigarette use. E-cigarette with high resistance will be used by an experienced smoker (tobacco flavor liquid, 12 mg nicotine, 4 sec puffs, 20-30 seconds inter-puff interval). Duration of exposure: 30 minutes.~All study subjects will participate in this arm as the study has a cross-over design.
Study: NCT04554368

Intervention type: PROCEDURE
Intervention: intra-arterial contrast enhanced Flat Detector CT
Description: After femoral artery puncture, FDCT scan (if necessary) and IA-CEFDCT scan were performed on a single flat-detector angiography system (Allura Xper FD20, Philips Medical systems, Best, the Netherlands), respectively. FDCT was acquired with the following acquisition parameters: 20s rotation, 220° rotation, 617 single frames at a frame rate of 30/s, 48cm detector field of view, 1024 acquisition matrix. Images were reconstructed using a soft-tissue kernel with an isotropic voxel size of 0.9 × 0.9 × 0.9 mm on a dedicated workstation for FPCT data (XperCT Dual 3.2.0). For image analysis, these isotropic FDCT data were viewed in the axial plane with 5 mm slice thickness.
Study: NCT01334073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib plus everolimus
Description: Patients will take both drugs orally, every day, without planned rest period (AX bid and EV once a day). By convention one cycle is 28 days. At the first cycle patients will take one week of AX single agent before starting EV. Patients will be treated at increasing dose levels (DLs) in successive cohorts of 3-6 patients according to the number of patients with dose limiting toxicities (DLT) until the maximum tolerated dose
Study: NCT01053676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanthanum Carbonate (Fosrenol, BAY77-1931) Granule
Description: BAY77-1931 Granule TID for 4 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lanthanum Carbonate (Fosrenol, BAY77-1931) Chewable tablet
Description: BAY77-1931 Chewable tablet TID for 4 days
Study: NCT01723306

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Gene Modified T Cells
Description: Subjects will undergo T cell leukopheresis. The collected T cells will be genetically modified, and then re-infused peripherally. IL2 will be given concomitantly for 30 days post modified T cell infusion via CADD pump.
Study: NCT02302911

Intervention type: BEHAVIORAL
Intervention: Early intensive behavioral intervention
Description: at least 10 hours a week of early intensive behavioral intervention

Intervention type: BEHAVIORAL
Intervention: Early intensive eclectic intervention
Description: at least 10 hours a week of early intensive eclectic intervention

Intervention type: OTHER
Intervention: Treatment as usual
Description: receipt of any Intervention that is less intensive than 10 hours a week
Study: NCT03950986

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified clinical reminders
Description: Clinical reminders for the vaccines of interest will be bundled into a single reminder, and other changes made to streamline the design and reduce provider burden. Other changes include an immunization dashboard that relays a patient's vaccination status and talking points for providers to use in their dialogues with patients.
Study: NCT00661375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexavar (Sorafenib, BAY43-9006)
Description: BAY 43-9006 400mg b.i.d. Treatment will continue until progression of underlying disease, unacceptable toxicity whose causal relationship to the study drug cannot be ruled out and which requires discontinuation of the drug, or consent withdrawal.
Study: NCT03607227

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: Active substance. Levobupivacaine 3.75 mg/ml 15 ml is given as a bolus injection at start of surgery, followed by ropivacaine 2 mg/ml continous infusion 5-8 ml/h from the end of surgery until end of intervention at the fourth to seventh postoperative day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Placebo. Saline solution (NaCl 0.9%) is given in equivalent intervals and doses as the active substances.
Study: NCT03734510

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Supplement: hesperidin and flaxseed
Description: 2 capsules hesperidin and 30 g flaxseed

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Supplement: hesperidin
Description: 2 capsules hesperidin

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Supplement: flaxseed
Description: 30 g flaxseed

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: no supplementation
Study: NCT02603523

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Senior Dance
Description: The Senior Dance classes consist of different choreographies, which include rhythmic and simple movements with rhythmic folk songs. During the classes, participants can practice the movements sitting or standing, quickly or slowly, in circles, individually, in pairs or in small groups. The concentration required to learn the choreographies challenges balance, motor coordination and cognitive function.
Study: NCT02822365

Intervention type: PROCEDURE
Intervention: Computed Tomography
Description: Undergo PET/CT scan as clinically indicated (Note: CT is for attenuation correction and not for diagnostic purposes).

Intervention type: DEVICE
Intervention: Imaging Phantoms
Description: Undergo limited field of view PET scan with the Pocket Phantom placed nearby to assist in scanner calibration. No additional PET tracer will be used.

Intervention type: PROCEDURE
Intervention: Positron Emission Tomography
Description: Undergo PET/CT scan as clinically indicated.
Study: NCT04763525

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pythagorean Self-Awareness Intervention(PSAI)
Description: The PSAI is a mental, stress-management technique that promotes self-awareness, cognitive reconstruction and self-improvement based on the Golden Verses moral framework of the ancient Greek philosopher Pythagoras. The individual must practice the technique twice daily( at bed-time and in the morning, every day, at home) and through a 3-stage internal dialogue (recall of daily events, inspection of related thoughts and emotions and self-appraisal)is encouraged to detect wrong choices and unhealthy behaviours and initiate self-correction towards a healthier lifestyle.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pythagorean Self-Awareness Intervention(PSAI)
Description: The PSAI is a mental, stress-management technique that promotes self-awareness, cognitive reconstruction and self-improvement based on the Golden Verses moral framework of the ancient Greek philosopher Pythagoras. The individual must practice the technique twice daily( at bed-time and in the morning, every day, at home) and through a 3-stage internal dialogue (recall of daily events, inspection of related thoughts and emotions and self-appraisal)is encouraged to detect wrong choices and unhealthy behaviours and initiate self-correction towards a healthier lifestyle.
Study: NCT04228419

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Shoulder Arthroplasty
Description: Replacement of the shoulder joint (ball and socket, or humeral head and glenoid) using prosthetic components.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reverse Shoulder Arthroplasty
Description: Replacement of the shoulder joint like the TSA, however the orientation of the ball and socket is reversed.
Study: NCT01774942

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Procedure/Surgery
Description: All teeth were extracted and replaced by a set of provisional full dentures in upper and lower jaws. Three months after extractions, dental implants were surgically placed and mucosa sutured over them. Three monts later, the dentures were re-lined and fitted onto the implants. Blood draw done by phlebotomist.
Study: NCT02039947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib will be provided as 50 mg and 75 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib will be provided as 50 mg and 75 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib will be provided as 50 mg and 75 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib will be provided as 50 mg and 75 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib will be provided as 0.5 mg and 2.0 mg tablets
Study: NCT03794063

Intervention type: OTHER
Intervention: Robson 10 group classification system
Description: WHO proposed the Robson classification system as a global standard for assessing, monitoring and comparing caesarean section rates within healthcare facilities over time, and between facilities. It classifies women in 10 groups based on their obstetric characteristics (parity, previous CS, gestational age, onset of labour, fetal presentation and number of fetuses) without needing the indication for CS.
Study: NCT02802475

Intervention type: BIOLOGICAL
Intervention: vena punction

Intervention type: BIOLOGICAL
Intervention: vena punction